The US FDA has cleared the first-in-class tyrosine kinase 2 (Tyk2) inhibitor as Sotyktu, and BMS says it now plans to launch the new drug later this month, aiming to mount a challenge to Amgen's $ ...
The deal – which is worth up to $905 million with an upfront fee of $90 million – gives BMS full control of BridgeBio's experimental SHP2 inhibitor BBP-398, which is already in a phase 1 trial ...
Microsoft Defender, which is built into Windows, can do this too. (Microsoft changed the name from Windows Defender several years ago, but it’s the same program.) Some antivirus suites also run ...
BMS clocked $224 million in worldwide sales for the cell therapy in the third quarter, more than double Q3 2023 thanks to its new leukemia indication as well as mantle cell lymphoma, for which the ...